| Literature DB >> 35566251 |
Tzu-Chuan Ho1, Chin-Chuan Chang2,3,4,5, Hung-Pin Chan6, Tze-Wen Chung7, Chih-Wen Shu1, Kuo-Pin Chuang8, Tsai-Hui Duh9,10, Ming-Hui Yang11,12, Yu-Chang Tyan1,2,3,8,10,13,14,15.
Abstract
Hydrogels are crosslinked polymer chains with three-dimensional (3D) network structures, which can absorb relatively large amounts of fluid. Because of the high water content, soft structure, and porosity of hydrogels, they closely resemble living tissues. Research in recent years shows that hydrogels have been applied in various fields, such as agriculture, biomaterials, the food industry, drug delivery, tissue engineering, and regenerative medicine. Along with the underlying technology improvements of hydrogel development, hydrogels can be expected to be applied in more fields. Although not all hydrogels have good biodegradability and biocompatibility, such as synthetic hydrogels (polyvinyl alcohol, polyacrylamide, polyethylene glycol hydrogels, etc.), their biodegradability and biocompatibility can be adjusted by modification of their functional group or incorporation of natural polymers. Hence, scientists are still interested in the biomedical applications of hydrogels due to their creative adjustability for different uses. In this review, we first introduce the basic information of hydrogels, such as structure, classification, and synthesis. Then, we further describe the recent applications of hydrogels in 3D cell cultures, drug delivery, wound dressing, and tissue engineering.Entities:
Keywords: 3D cell culture; drug delivery; hydrogel; medical application; tissue engineering; wound dressing
Mesh:
Substances:
Year: 2022 PMID: 35566251 PMCID: PMC9104731 DOI: 10.3390/molecules27092902
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1The number of publications related to hydrogels in the biomedical field in the past five years. The data was obtained from the biomedical database PubMed, using the search term “hydrogel”.
Figure 2Classification of hydrogels.
Figure 3Simple diagram of homopolymer hydrogels, copolymer hydrogels, semi-IPNs, and IPN hydrogels.
Figure 4The structure of hydrogels (chemical linking and physical junctions).
Figure 5Methods of chemical and physical crosslinking for hydrogels preparation.
Natural, synthetic, and semi-synthetic hydrogels for 3D cell cultures.
| Source of Hydrogels | Properties | Materials | Cell | Applications |
|---|---|---|---|---|
| Natural | Provide comparable viscoelasticity and fibrils to the ECM; having good biocompatibility; endogenous factors can support cellular activity | Collagen | Rat chondrocyte [ | Maintain the chondrocyte phenotype [ |
| HA | hiPSC-NPCs [ | Promote the neural differentiation of hiPSC-NPCs [ | ||
| Fibrin | HUVECs/hMSCs [ | Prevascular formation of HUVECs, improve cell viability and proliferation of hMSCs and enhance their osteogenic differentiation and bone mineral deposition [ | ||
| Alginate | hESCs/hiPSCs [ | Enhance the generation of retinal pigmented epithelium and neural retina of hESCs/hiPSCs [ | ||
| Synthetic | Have the good mechanical strength to provide structural support for various cell types in 3D cell culture | PVA | mHSCs [ | Enhance the expansion of murine hematopoietic stem cells (mHSCs) [ |
| PEG | hiPSCs [ | Enhance the hematopoietic differentiation of hiPSCs [ | ||
| Semi-synthetic | Have a feature of ECM microenvironment and faster stress relaxation | HA–PEG | hiPS-HEPs [ | Enhance viability and functionality of hiPS-HEPs [ |
| RGD–alginate–PEG | Fibroblasts and mMSCs [ | Increase the spread and proliferation of fibroblasts and the osteogenic differentiation of mMSCs [ |
Smart hydrogels for drug delivery.
| Hydrogels | Drug | Materials | Sustained-Release Time | Proposed Applications | Ref. |
|---|---|---|---|---|---|
| Thermoresponsive hydrogel | Dexamethasone | HPMA | More than 30 days | Osteoarthritis and rheumatoid arthritis | [ |
| Topotecan | Poloxamer 407 and poloxamer 188 | 28 days | Colorectal cancer | [ | |
| Lamivudine and zidovudine | Pluronic® F-127 | 168 h | AIDS | [ | |
| Antibody | PEGMA | 13 days | Enhance the efficacy of antibody treatment | [ | |
| pH-responsive hydrogel | Bortezomib | mPEG-LUT | 50 h | Colorectal cancer | [ |
| Amifostine (S-2(3-aminopropylamino) ethyl phosphorothioate | MAC-g-PCL | 6 h | Acute radiation syndrome | [ | |
| Photoresponsive hydrogel | Doxycycline | SPCOOH modified-silicone-hydrogel (poly(HEMA-co-PEGMEA)) | 42 h | Inflammation disease | [ |
| Insulin | BP, pNIPAM, PEG, and ETPTA | Not detected | Diabetic disease | [ | |
| Daul-responsive hydrogel | |||||
| pH/thermo | Doxorubicin chemosensitizer curcumin | poly (NIPAAm-co-DMAEMA) | 168 h | Colon cancer |
[ |
| Methotrexate | 50 h | Breast cancer |
[ | ||
| pH/redox | Magnesium ions | poly (NIPAAm-co-DMAEMA) | 6 h | Ionic therapeutics | [ |